
<table>
<tbody>
<tr>
<td data-label="Date">2013</td>
<td data-label="Funding Source">Cancer Research UK</td>
<td data-label="Title/Amount">"Systematic development of the anti-avﬂ6 imaging peptide A20FMDV2 for use as an anti-cancer therapeutic"<br /> £96,650</td>
</tr>
<tr>
<td data-label="Date">2013</td>
<td data-label="Funding Source">AstraZeneca UK Limited</td>
<td data-label="Title/Amount">* "Use and development of a novel higher throughout 3D organotypic invasion assay for assessing the effects of stromal fibroblasts on drug cvtotoxicity"<br /> £26,124</td>
</tr>
<tr>
<td data-label="Date">2013</td>
<td data-label="Funding Source">Medical Research Council</td>
<td data-label="Title/Amount">"MRI to reduce and refine the use of mice in cancer and trauma research"<br /> £342,469</td>
</tr>
<tr>
<td data-label="Date">2013</td>
<td data-label="Funding Source">BBSRC</td>
<td data-label="Title/Amount">(*As above)<br /> £101,520</td>
</tr>
<tr>
<td data-label="Date">2012</td>
<td data-label="Funding Source">Breast Cancer Campaign</td>
<td data-label="Title/Amount">"Novel transgenic mouse models for identifying biomarkers of†avﬂ6/HER2-dependent breast cancer"<br />£221,817</td>
</tr>
<tr>
<td data-label="Date">2012</td>
<td data-label="Funding Source">ADC THERAPEUTICS SARL</td>
<td data-label="Title/Amount">Experiment using A375puro and A375pb6<br /> £41,793</td>
</tr>
<tr>
<td data-label="Date">2012</td>
<td data-label="Funding Source">BBSRC</td>
<td data-label="Title/Amount">* "The role of integrins in the regulation of fibroblast activity and activation"<br /> £100,173</td>
</tr>
<tr>
<td data-label="Date">2012</td>
<td data-label="Funding Source">GlaxoSmithKline Research &amp; Development</td>
<td data-label="Title/Amount">(*As above)<br /> £32,000</td>
</tr>
<tr>
<td data-label="Date">2012-2015</td>
<td data-label="Funding Source"><a href="http://www.pcrf.org.uk/" target="_blank">Pancreatic Cancer Research Fund</a></td>
<td data-label="Title/Amount">"Using transgenic mourse models to develop integrin†avﬂ6-targetted therapy of pancreatic cancer"<br />£179,992</td>
</tr>
<tr>
<td data-label="Date">2011-2013</td>
<td data-label="Funding Source">DebRA</td>
<td data-label="Title/Amount"><em>Co-invesigator with Edel O'Toole</em>: "Dissecting the role of basement membrane components in a xenograft model of cutaneous SCC"<br />£114,960</td>
</tr>
<tr>
<td data-label="Date">2010</td>
<td data-label="Funding Source">Medical Research Council</td>
<td data-label="Title/Amount">"The Evaluation of the†avﬂ6†Integrin as a Biomarker and Therapeutic Target for Idiopathic Pulmonary Fibrosis"</td>
</tr>
<tr>
<td data-label="Date">2010</td>
<td data-label="Funding Source">BBSRC</td>
<td data-label="Title/Amount">"Empty virus like particles (eVLPs) as bio-compatible targeted drug-delivery vehicles"<br /> £10,043</td>
</tr>
<tr>
<td data-label="Date">2009-2011</td>
<td data-label="Funding Source">Pancreatic Cancer Research Fund</td>
<td data-label="Title/Amount">"Development of imaging and therapy of pancreatic cancer by targeting the integrin avﬂ6"<br />£149,170</td>
</tr>
<tr>
<td data-label="Date">2009-2012</td>
<td data-label="Funding Source">Breast Cancer Campaign</td>
<td data-label="Title/Amount"><em>Co-applicant with Prof. Louise Jones (PI):</em> "Functional and clinical significance of loss of the tumour-suppressor MMP-8 in myoepithelial cells of DCIS"<br />£109,280</td>
</tr>
<tr>
<td data-label="Date">2009-2012</td>
<td data-label="Funding Source">Medical Research Council</td>
<td data-label="Title/Amount"><em>Co-applicant with Gisli Jenkins:</em> "The evaluation of the†avﬂ6 integrin as a biomarker and therapeutic target for idiopathic pulmonary fibrosis."<br />£419,472</td>
</tr>
<tr>
<td data-label="Date">2009</td>
<td data-label="Funding Source">Aura Biosciences</td>
<td data-label="Title/Amount">"Efficacy of Nanoparticles in Cancer Therapy"<br /> £54,313</td>
</tr>
<tr>
<td data-label="Date">2009-2011</td>
<td data-label="Funding Source">Medical Research Council</td>
<td data-label="Title/Amount">"Establishing efficacy and molecular mechanisms of integrin avﬂ6 -directed human-antibody therapy of cancer"<br />£221,494</td>
</tr>
<tr>
<td data-label="Date">2008</td>
<td data-label="Funding Source">Breast Cancer Campaign</td>
<td data-label="Title/Amount">"Effects of Integrin†avﬂ6†expression"<br />£183,727</td>
</tr>
<tr>
<td data-label="Date">2008</td>
<td data-label="Funding Source">Cancer Research UK</td>
<td data-label="Title/Amount">UK Meeting Award<br /> £1,000</td>
</tr>
<tr>
<td data-label="Date">2009</td>
<td data-label="Funding Source">DebRA Austria</td>
<td data-label="Title/Amount">"Pathological &amp; immunological analysis of RDEB-SCC for the development of novel biomarkers"<br /> £101,344</td>
</tr>
</tbody>
</table>